BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan's Sysmex Corp teams up with QIAGEN for global cancer companion diagnostics

July 2, 2021 | News

QIAGEN expects significant benefits for pharma companies and cancer patients worldwide



QIAGEN has announced a global strategic alliance with Japan's Sysmex Corporation for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN's leadership in this field and Sysmex's Plasma-Safe-SeqS technology for next generation sequencing (NGS).

The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultra-sensitive liquid biopsy companion diagnostics.

QIAGEN and Sysmex have a longstanding partnership, which, for example, provides the *ipsogen* JAK2 blood-cancer test in Japan. Cancer companion-diagnostics products will be launched by QIAGEN and Sysmex in various regions of the world.

"The alliance with QIAGEN promises Sysmex a great application for Sysmex's Plasma-Safe-SeqS technology, which can detect gene mutations of cancer in blood with ultra-high sensitivity. We believe that QIAGEN is the best for Sysmex to expand this globally," said Hiroshi Kanda, Member of the Managing Board and Senior Executive Officer, Head of Corporate Business Development at Sysmex.